NCT03728361 2025-12-18
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
Clinical Trials
17 trialsNCT04339036 2025-12-10
CapTemY90
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
NCT04919226 2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3 Active not recruiting
NCT05554003 2024-11-18
MeTe
European Institute of Oncology
Phase 2 Recruiting
NCT06038461 2024-10-01
An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2 Recruiting
NCT04893785 2024-06-18
CABOTEM
National Cancer Institute, Naples
Phase 2 Recruiting
NCT05647954 2022-12-13
A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver
Taizhou Hanzhong biomedical co. LTD
Phase 3 Unknown
NCT03079440 2022-12-06
TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors
Asan Medical Center
Phase 2 Completed
NCT02943733 2022-09-23
Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs
University of Wisconsin, Madison
Phase 1 Terminated
NCT02698410 2020-10-01
ATLANT
Ipsen
Phase 2 Completed
NCT02231762 2019-05-06
SONNET
Ipsen
Phase 2 Completed
NCT02831179 2017-09-28
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
Vanderbilt-Ingram Cancer Center
Phase 1 Withdrawn
NCT03279601 2017-09-12
Study to Compare Capecitabine Combined With Dacarbazine(CAPDTIC) Versus Capecitabine Combined Temozolomide(CAPTEM) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Tumor
Peking University
Phase 2 Unknown
NCT03204032 2017-06-29
A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor
ChineseAMS
Phase 2 Unknown
NCT00869050 2016-07-25
Capecitabine and Temozolomide for Neuroendocrine Cancers
Columbia University
Phase 2 Completed
NCT00137774 2013-04-09
Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00165230 2009-04-28
Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors
Dana-Farber Cancer Institute
Phase 2 Completed